The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The investment will enable the company to enter European markets as well as enhance margins in current markets
Sanjeev is currently the Country President for AstraZeneca Malaysia
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
EC grants conditional marketing authorization based on the EFFISAYIL trial
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Subscribe To Our Newsletter & Stay Updated
